Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Classes of BRAF mutation exhibit distinct clinicopathologic and molecular characteristics. A, Subdivision of the large bowel into the proximal and distal colorectum. Proportions of colorectal cancers in each location are shown by BRAF mutation class. B, CMS classifications of BRAF-mutant colorectal cancers by mutation class. The differences between class 2 or 3 versus class 1 (V600E) were highly significant (P < 0.001). No significant difference was observed between classes 2 and 3 (P = 0.270). C and D, Sanger sequencing chromatograms highlighting the spatial co-occurrence of BRAF and additional Ras pathway mutations in two colorectal cancers. Two regions of each cancer were microdissected, DNA was extracted, and relevant exons were PCR-amplified prior to Sanger sequencing. Illustrative results are shown. The co-occurrence of BRAFG466V and NRASG12D can be observed in tumor 1 (C), and of BRAFD594G and KRASL19F in tumor 2 (D). This analysis does not exclude fine-scale spatial mixing of distinct subclones but is consistent with the two mutations tested being present in the same tumor cells. (Created with BioRender.com.)

More information Original publication

DOI

10.1158/1541-7786.28703756

Type

Other

Publication Date

2025-04-01T00:00:00+00:00